Larvol Delta - A-ProofofActivity-Study-With-Orticumab-in-Subjects-With-Psoriasis-and-Cardiometabolic-Risk-Factors

orticumab (BI 204) - Roche, Abcentra

http://clinicaltrials.gov/ct2/show/NCT04776629

Sep 10, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next